Remove tag pharmas-response-covid-19
article thumbnail

3 ways pharma marketers can draw inspiration from digitally-native brands

pharmaphorum

Companies like prescription glasses firm Warby Parker, shoe brand Rothy’s and tele-dentistry’s SmileDirectClub have grown up in today’s digitally native environment and can offer some key pointers for pharma. As part of this, a number of big pharma companies are also racing to develop a safe and effective vaccine for the coronavirus.

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Three out of the seven patients demonstrated objective responses and remain on treatment after more than eight months.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A roadmap for adopting New Science 

pharmaphorum

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research. And 65% of pharma sales rep meetings were held virtually. About the author.

article thumbnail

Developing point-of-care CAR T manufacturing

European Pharmaceutical Review

The CAR T cells need to persist in the blood to expand and elicit maximal effect, and there is a correlation between expansion and persistence and response. Second, the production and delivery of CAR T cells necessitates close collaboration between the pharma industry and academic (usually transplant) departments.

article thumbnail

Risk sharing agreements soar as market access risk increases

Pharmaceutical Technology

On 16 March, Watt spoke at GlobalData webinar titled “Pharma [POLI]: Market Access Risk Outlook”, providing a current outlook on the pharmaceutical pricing and reimbursement environments around the world, including key reforms, risks and opportunities. Free Report What is the Global Healthcare and Pharma Market Q2 Outlook?